

# Bone Medical

ASX/MEDIA RELEASE

## **Bone received Notice of Allowance for Moziac arthritis patent in US**

*Important patent securing future developments*

**5 December 2007:** Bone Medical Limited (ASX:BNE) has received notice of allowance for its in-licensed drug discovery technology Mozaic by the US Patent Office. Mozaic creates novel oligopeptides for the BN006 rheumatoid arthritis (RA) programme.

The Mozaic patent has already been granted in Europe to cover methods of applying the technology and the US patent protects the composition generated during the discovery process.

The Mozaic technology is a revolutionary concept in drug discovery. Like other technologies it works through bringing building blocks together to bind to biological targets. It differs from other approaches in that the building blocks cover the surface of nanoparticles that are able to interact with cell receptors very effectively changing behaviour in a therapeutically advantageous way.


The Mozaic technology has already proved itself in having given rise to a series of molecules which can inhibit production of TNF (Tumour necrosis factor) by macrophages and thus has potential as a treatment for rheumatoid arthritis.

The current therapy of choice for RA is TNF blockade – mopping up TNF in the bloodstream using monoclonal antibodies. While this is an effective therapy it does involve costly injections and there are concerns about increased susceptibility to infectious diseases and particular cancers.

As BN006 acts only on the inflammatory cells that produce TNF its action should be more specific as an inexpensive pill option.

Bone has also used the Mozaic technology to identify structures which can up-regulate osteoblasts and down-regulate osteoclasts, showing promise as a new generation of osteoporosis treatments.

- ENDS -



# Bone Medical

## **Enquiries:**

Dr Roger New  
Chairman  
Mobile: +44 781 806 8012  
Australian Office: +61 8 9355 5123

Rudi Michelson  
Monsoon Communications  
+61 3 9620 3333

Troels Jordansen  
Managing Director  
Mobile: + 44 79 1713 0019

Or visit: [www.bonemedical.com](http://www.bonemedical.com)

## **About Bone Medical Limited**

Bone Medical Limited is an international biopharmaceutical development company positioned to exploit the growing market in the treatment of bone disease particularly in osteoporosis and arthritis. Bone has a portfolio of biopharmaceutical development projects for the treatment of bone disease including,

### Osteoporosis

- Capsitonin™ oral calcitonin
- Perthoxal™ oral parathyroid hormone
- bone cell regulators BN005 & BN008

### Arthritis

- TNF regulators BN006
- joint protection & collagen tolerance BN007